This study aims to describe the patient population treated and the real-life patients'
experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis
vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling
dermatologists and patients to optimize its use in the long term management of psoriasis.